Patents by Inventor Dale Umetsu

Dale Umetsu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Agents that modulate RGMb-neogenin-BMP signaling and methods of use thereof
    Patent number: 11485787
    Abstract: The present invention relates to compositions and methods for the modulation RGMb-Neogenin-BMP signaling.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: November 1, 2022
    Assignees: Dana-Farber Cancer Institute, Inc., Boston Children's Hospital
    Inventors: Rosemarie Dekruyff, Gordon J. Freeman, Dale Umetsu, Sanhong Yu, Yanping Xiao
  • Agents that modulate immune cell activation and methods of use thereof
    Patent number: 11359020
    Abstract: The present invention relates to compositions and methods for the immunomodulation mediated by the interaction of PD-L2 and RGMb.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: June 14, 2022
    Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College, Children's Medical Center Corporation
    Inventors: Gordon J. Freeman, Arlene H. Sharpe, Yanping Xiao, Loise Francisco, Rosemarie Dekruyff, Dale Umetsu
  • AGENTS THAT MODULATE IMMUNE CELL ACTIVATION AND METHODS OF USE THEREOF
    Publication number: 20200095325
    Abstract: The present invention relates to compositions and methods for the immunomodulation mediated by the interaction of PD-L2 and RGMb.
    Type: Application
    Filed: September 16, 2019
    Publication date: March 26, 2020
    Inventors: Gordon J. Freeman, Arlene H. Sharpe, Yanping Xiao, Loise Francisco, Rosemarie Dekruyff, Dale Umetsu
  • Agents that modulate immune cell activation and methods of use thereof
    Patent number: 10457733
    Abstract: The present invention relates to compositions and methods for the immunomodulation mediated by the interaction of PD-L2 and RGMb.
    Type: Grant
    Filed: August 2, 2013
    Date of Patent: October 29, 2019
    Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Gordon J. Freeman, Arlene H. Sharpe, Yanping Xiao, Loise Francisco, Rosemarie Dekruyff, Dale Umetsu
  • AGENTS THAT MODULATE RGMb-NEOGENIN-BMP SIGNALING AND METHODS OF USE THEREOF
    Publication number: 20160347844
    Abstract: The present invention relates to compositions and methods for the modulation RGMb-Neogenin-BMP signaling.
    Type: Application
    Filed: February 5, 2015
    Publication date: December 1, 2016
    Inventors: Rosemarie Dekruyff, Gordon J. Freeman, Dale Umetsu, Sanhong Yu, Yanping Xiao
  • PRODUCTION AND THERAPEUTIC USES OF TH1-LIKE REGULATORY T CELLS
    Publication number: 20160136204
    Abstract: A unique CD4+CD25+ regulatory T cell population develops from naive CD4+CD25? T cells during a TH1 polarized immune response (called TH1-TR cells). These TH1-TR cells can be generated by contacting naïve T cells with mature CD8?+ dendritic cells (DCs) that have been exposed to a TH1 polarizing adjuvant and, in some cases, an antigen of interest. The TH1-TR are identified by their expression of the cytokines IL-10 and IFN-?, the transcriptional regulators T-bet and FoxP3, and the cell surface molecules CD4, CD25, CD69, CD44 and ICOS.
    Type: Application
    Filed: September 29, 2015
    Publication date: May 19, 2016
    Inventors: Dale Umetsu, Rosemarie Dekruyff, Omid Akbari, Philippe Stock
  • Agents That Modulate Immune Cell Activation and Methods of Use Thereof
    Publication number: 20150299322
    Abstract: The present invention relates to compositions and methods for the immunomodulation mediated by the interaction of PD-L2 and RGMb.
    Type: Application
    Filed: August 2, 2013
    Publication date: October 22, 2015
    Applicants: Dana-Farber Cancer Institute, Inc., Boston Children's Hospital, President and Fellows of Harvard College
    Inventors: Gordon J. Freeman, Arlene H. Sharpe, Yanping Xiao, Loise Francisco, Rosemarie Dekruyff, Dale Umetsu
  • Production And Therapeutic Uses Of Th1-Like Regulatory T Cells
    Publication number: 20080241174
    Abstract: A unique CD4+CD25+ regulatory T cell population develops from naive CD4+CD25? T cells during a TH1 polarized immune response (called TH1-TR cells). These TH1-TR cells can be generated by contacting naïve T cells with mature CD8?+ dendritic cells (DCs) that have been exposed to a TH1 polarizing adjuvant and, in some cases, an antigen of interest. The TH1-TR are identified by their expression of the cytokines IL-10 and IFN-?, the transcriptional regulators T-bet and FoxP3, and the cell surface molecules CD4, CD25, CD69, CD44 and ICOS.
    Type: Application
    Filed: March 18, 2005
    Publication date: October 2, 2008
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Dale Umetsu, Rosemarie Dekruyff, Omid Akbari, Philippe Stock
  • Methods for inhibition of NKT cells
    Publication number: 20060116332
    Abstract: Molecules that interact with the NKT cell antigen receptor and its counterpart antigen presenting molecule, but which inhibit the NKT cell immune function, are administered to a patient. Conditions of particular interest include the treatment of systemic lupus erythematosus (SLE), cancer, atherosclerosis, and allergic disease. In some embodiment of the invention, the inhibitory agent is an anergizing glycolipid, for example ?-galactosylceramide. Pharmaceutical formulations of such glycolipids are provided, and find use in the treatment of diseases involving undesirable NKT cell activation.
    Type: Application
    Filed: November 2, 2005
    Publication date: June 1, 2006
    Inventors: Samuel Strober, Everett Meyer, Dale Umetsu
  • T cell regulatory genes associated with immune disease
    Publication number: 20050095593
    Abstract: A genetic locus and corresponding family of proteins associated with regulation of immune development, function, and cell survival are provided. The locus comprising the TIM family is genetically associated with immune dysfunction, including atopy, autoimmunity, inflammatory bowel disease, dysplasia, and susceptibility to blood-bourne infectious diseases. Polymorphisms in the human TIM-1 gene and exposure to Hepatitis A Virus (HAV) are shown to be associated with protection from the development of atopy.
    Type: Application
    Filed: September 15, 2003
    Publication date: May 5, 2005
    Inventors: Jennifer McIntire, Rosemarie Dekruyff, Dale Umetsu, Gordon Freeman